Noxopharm Ltd. · ASX:NOX
Noxopharm — Kalkine Invest Nest 2020 Small Cap Investor Conference
27 slides from Noxopharm's conference presentation, Feb 27, 2020
Slide 1: Noxopharm Corporate Presentation February 2020
For personal use only 27 February 2020 Sydney, Australia Noxopharm Corporate Presentation February 2020 Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached corporate presentation, “Kalkine Invest Nest Presentation 27 February 2020”. This document will be used at the K
Slide 2: Forward Looking Statements
For personal use only expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward
Slide 3: Noxopharm Limited Veyonda - Kalkine Invest-Nest Presentation
February 2020 For personal use only Noxopharm Limited Veyonda® Kalkine Invest-Nest Presentation – 27 Feb 2020 DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be
Slide 5: Prostate Cancer, Veyonda, Clinical Program, Market Potential
Dr Gisela Mautner, MD-PHD, MPH, MBA, FACPE For personal use only Chief Medical Officer Prostate Cancer Veyonda® DARRT-Studies Veyonda® LuPIN-Study Clinical Program Veyonda® Market Potential © 2020 Noxopharm Ltd. All rights reserved.
Slide 6: Did you know? Prostate cancer diagnoses each day in Australia
Did you know? EACH DAY For personal use only in Australia 50 MEN are diagnosed with PROSTATE CANCER © 2020 Noxopharm Ltd. All rights reserved.
Slide 7: Men developing prostate cancer before they turn
For personal use only 1 in 5 men develop prostate cancer before they turn 85 © 2019 Noxopharm Ltd. All rights reserved.
Slide 8: Prostate cancer in India
In India ➢ The prevalence of prostate cancer in India was For personal use only previously thought to be far lower compared to western countries ➢ BUT … ―Increased migration from rural to urban areas ―Changing life styles and diet ―Increased awareness ―Easier access to medical facilities ―… ―More ca
Slide 9: Drug Development Process: Veyonda
Drug Development Process For personal use only Veyonda® © 2020 Noxopharm Ltd. All rights reserved.
Slide 10: Veyonda – Our Lead Drug
Veyonda® – Our Lead Drug Veyonda® For personal use only Low-dose Radio Therapy Cancer cells Immune cells © 2020 Noxopharm Ltd. All rights reserved.
Slide 11: Prostate Cancer and Treatment Options
Prostate Cancer and Treatment Options use only Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer Surgery Chemical Androgen Palliative therapy Chemo- and/or local castration & receptor Rising PSA levels in blood therapy radiotherapy therapy inhibitors For personal Veyonda® DARR
Slide 12: Veyonda – Clinical Study DARRT-1
1 Veyonda® – Clinical Study DARRT-1 For personal use only ➢ 26 men enrolled with late-stage prostate cancer ➢ Metastatic castration-resistant prostate cancer (mCRPC) ➢ Progressive disease ➢ No remaining standard treatment options ➢ Eligible for palliative RT for symptomatic relief DARRT = Direct and
Slide 13: DARRT-1: Efficacy Results - PSA
11 DARRT-1: Efficacy Results - PSA ➢ Veyonda® in combination with radiation therapy For personal use only appeared to be safe and well-tolerated1 ➢ In the 16* patients who were evaluable at 6 months1 Over 50% drop in PSA in 5/16 patients * 9 patients lost to follow-up, died or withdrew from study PS
Slide 14: DARRT-1: Efficacy Results - Pain
11 DARRT-1: Efficacy Results - Pain ➢ Veyonda® in combination with radiation therapy For personal use only appeared to be safe and well-tolerated1 ➢ In the 16* patients who were evaluable at 6 months1 Over 30% drop in pain levels In 10/16 patients * 9 patients lost to 4 patients became follow-up, di
Slide 15: DARRT-1: Efficacy Results – Tumour Response
11 DARRT-1: Efficacy Results – Tumour Response ➢ In the 15* patients who were evaluable at 6 For personal use only months1 Tumors stopped growing in 9 patients Tumors reduced in size in 1 patient In summary, combination therapy of Veyonda® and radiotherapy showed major benefits to patients and under
Slide 16: Veyonda Acts in a Unique Space
Veyonda® Acts in a Unique Space For personal use only 1 drug RT & Veyonda® Life-extending treatment Palliative treatment 1 drug 1 drug RT & Veyonda® 1 drug 1 drug 1 drug RT & Veyonda® 1 drug 1 drug 1 drug 1 drug RT & Veyonda® Irrespective of how many new drugs are coming to market, they will general
Slide 17: DARRT-2 Trial: In Planning
2 DARRT-2 Trial: In Planning ➢ Building on the experience and data of DAART-1 For personal use only ➢ Phase 2 trial ➢ Multinational ➢ Min. 60 patients ➢ Same patient population as in DARRT-1 ➢ Radiation therapy plus repeated cycles of Veyonda® ➢ Medical Advisory Boards established ➢ Protocol synopsi
Slide 18: Additional Opportunity in Prostate Cancer
Additional Opportunity in Prostate Cancer For personal use only External Radiation Internal Radiation ➢ Standard-of-Care ➢ Experimental ➢ Widely used ➢ Billion-dollar Acquisition by Novartis DARRT LuPIN © 2020 Noxopharm Ltd. All rights reserved.
Slide 19: LuPIN Trial: Key Interim Results
LuPIN Trial: Key Interim Results ❖ Comparison Veyonda® + 177Lu-PSMA-617 vs 177Lu-PSMA-617 alone For personal use only ▪ Progression-free survival (PFS) is a measure of the time from the start of treatment until the disease progresses. 2 months 177Lu-PSMA-617 alone 177Lu-PSMA-617 + 8.4 months Veyonda
Slide 20: LuPIN Trial: Key Interim Results
LuPIN Trial: Key Interim Results ❖ Veyonda® + 177Lu-PSMA-617 For personal use only ▪ Overall Survival (OS) is a measure of the time from the start of treatment until death. 17.1 months ✓ Median OS was 17.1 months – a remarkable result at this late stage of the disease ✓ The combination therapy was w
Slide 21: Veyonda - Pipeline
Veyonda® - Pipeline For personal use only Being In Explored Ongoing Completed Planning DARRT-1 Become standard of care adjunct to radiotherapy LuPIN in prostate cancer DARRT-2 CEP-1 Combined with chemotherapy CEP-2 Combined with IONIC immunotherapy © 2020 Noxopharm Ltd. All rights reserved.
Slide 22: Market Potential – Radiotherapy in Prostate Cancer
Market Potential – Radiotherapy in Prostate Cancer For personal use only CURRENT treatment FUTURE treatment opportunity Prostate Cancer Radiotherapy Radiotherapy & alone Veyonda® © 2020 Noxopharm Ltd. All rights reserved.
Slide 23: Potential Market Opportunities – Radiotherapy plus Veyonda
Potential Market Opportunities – Radiotherapy plus Veyonda® For personal use only Prostate Cancer Others Palliative Breast Cancer radio therapy Thyroid Cancer Veyonda® Lung Cancer Kidney Cancer © 2020 Noxopharm Ltd. All rights reserved.
Slide 24: Corporate Overview
Mr Alex Hunter MBA, BE, GradDipCorpSecFinLaw, GradDipAppFin For personal use only Corporate Overview Executive Summary Company Details Veyonda® © 2020 Noxopharm Ltd. All rights reserved.
Slide 25: Executive Summary
Executive Summary ➢ ASX listed (NOX) since 2016 For personal use only ➢ Clinical stage drug development Company (mid-stage = substantially de-risked) ➢ Oncology focus. Proprietary drug Veyonda® ➢ Aiming at largest market sector in oncology – late-stage solid cancers where patients receiving just pal
Slide 26: Company Details
Company Details Noxopharm Limited (Feb 2020) Board and Key Management For personal use only Listed on Australian Securities Exchange (ASX:NOX) Dr Graham Kelly. PhD Chairman & CEO Shares on issue 152m Ian Dixon. PhD, MBA Non-Executive Director Share Price A$0.205-A$0.365 Peter Marks. MBA, BEc, LLB No
Slide 27: For further information please visit www.noxopharm.com
For personal use only For further information please visit www.noxopharm.com Veyonda® DISCOVER DEVELOP DELIVER ASX: NOX © 2020 Noxopharm Ltd. All rights reserved.
Noxopharm — Kalkine Invest Nest 2020 Small Cap Investor Conference on 6ix